SOPH Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -85.48% compared to Sophia Genetics SA's net margin of -2841.85%. Sophia Genetics SA's return on equity of -50.8% beat Addex Therapeutics's return on equity of 91.08%.

Sophia Genetics SA has a consensus price target of $6.80, signalling upside risk potential of 122.22%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 294.74%. Given that Addex Therapeutics has higher upside potential than Sophia Genetics SA, analysts believe Addex Therapeutics is more attractive than Sophia Genetics SA.

Sophia Genetics SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.600, suggesting its more volatile than the S&P 500 by 59.971%.

Sophia Genetics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sophia Genetics SA pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

Sophia Genetics SA quarterly revenues are $17.7M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Sophia Genetics SA's net income of -$15.2M is lower than Addex Therapeutics's net income of -$1.8M. Notably, Sophia Genetics SA's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sophia Genetics SA is 3.10x versus 14.04x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -85.48% compared to Sophia Genetics SA's net margin of -106.6%. Sophia Genetics SA's return on equity of -50.8% beat CRISPR Therapeutics AG's return on equity of -18.65%.

Sophia Genetics SA has a consensus price target of $6.80, signalling upside risk potential of 122.22%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.46 which suggests that it could grow by 111.36%. Given that Sophia Genetics SA has higher upside potential than CRISPR Therapeutics AG, analysts believe Sophia Genetics SA is more attractive than CRISPR Therapeutics AG.

Sophia Genetics SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.849, suggesting its more volatile than the S&P 500 by 84.861%.

Sophia Genetics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sophia Genetics SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

Sophia Genetics SA quarterly revenues are $17.7M, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Sophia Genetics SA's net income of -$15.2M is higher than CRISPR Therapeutics AG's net income of -$37.3M. Notably, Sophia Genetics SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sophia Genetics SA is 3.10x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

Molecular Partners AG has a net margin of -85.48% compared to Sophia Genetics SA's net margin of -2408.81%. Sophia Genetics SA's return on equity of -50.8% beat Molecular Partners AG's return on equity of -37.36%.

Sophia Genetics SA has a consensus price target of $6.80, signalling upside risk potential of 122.22%. On the other hand Molecular Partners AG has an analysts' consensus of $10.57 which suggests that it could grow by 172.72%. Given that Molecular Partners AG has higher upside potential than Sophia Genetics SA, analysts believe Molecular Partners AG is more attractive than Sophia Genetics SA.

Sophia Genetics SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Molecular Partners AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sophia Genetics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molecular Partners AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sophia Genetics SA pays -- of its earnings as a dividend. Molecular Partners AG pays out -- of its earnings as a dividend.

Sophia Genetics SA quarterly revenues are $17.7M, which are larger than Molecular Partners AG quarterly revenues of $787.5K. Sophia Genetics SA's net income of -$15.2M is lower than Molecular Partners AG's net income of -$12.8M. Notably, Sophia Genetics SA's price-to-earnings ratio is -- while Molecular Partners AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sophia Genetics SA is 3.10x versus 19.47x for Molecular Partners AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -85.48% compared to Sophia Genetics SA's net margin of --. Sophia Genetics SA's return on equity of -50.8% beat NLS Pharmaceutics's return on equity of --.

Sophia Genetics SA has a consensus price target of $6.80, signalling upside risk potential of 122.22%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 16226.53%. Given that NLS Pharmaceutics has higher upside potential than Sophia Genetics SA, analysts believe NLS Pharmaceutics is more attractive than Sophia Genetics SA.

Sophia Genetics SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sophia Genetics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sophia Genetics SA pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

Sophia Genetics SA quarterly revenues are $17.7M, which are larger than NLS Pharmaceutics quarterly revenues of --. Sophia Genetics SA's net income of -$15.2M is higher than NLS Pharmaceutics's net income of --. Notably, Sophia Genetics SA's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sophia Genetics SA is 3.10x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.